Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Bone and cancer: the osteoncology.

Ibrahim T, Mercatali L, Amadori D.

Clin Cases Miner Bone Metab. 2013 May;10(2):121-3. Review.

2.

Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom.

Lester JE, Dodwell D, Horsman JM, Mori S, Coleman RE.

Br J Cancer. 2006 Jan 16;94(1):30-5.

3.

Cancer treatment-induced bone loss in patients with breast or prostate cancer.

Maxwell C, Viale PH.

Oncol Nurs Forum. 2005 May 10;32(3):589-603. Review.

PMID:
15897934
4.

Emerging drugs for the management of cancer treatment induced bone loss.

Bertoldo F, Pancheri S, Zenari S, Boldini S.

Expert Opin Emerg Drugs. 2010 Jun;15(2):323-42. doi: 10.1517/14728211003631385. Review.

PMID:
20377485
5.

Cancer-treatment-induced bone loss, part 2.

Michaud LB, Goodin S.

Am J Health Syst Pharm. 2006 Mar 15;63(6):534-46. Review.

PMID:
16522890
6.

Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.

Brufsky AM.

Oncologist. 2008 Feb;13(2):187-95. doi: 10.1634/theoncologist.2007-0152. Review.

7.

Cancer-treatment-induced bone loss, part 1.

Michaud LB, Goodin S.

Am J Health Syst Pharm. 2006 Mar 1;63(5):419-30. Review.

PMID:
16484516
8.

[Epidemiology, management and cost of bone metastases from lung cancer].

Decroisette C, Galerneau LM, Hominal S, Chouaid C.

Rev Mal Respir. 2013 Apr;30(4):309-15. doi: 10.1016/j.rmr.2012.12.005. Epub 2013 Jan 11. Review. French.

PMID:
23664289
9.

[Cancer treatment-induced bone loss. Treatment for breast cancer].

Yamada K, Kohno N.

Clin Calcium. 2008 Apr;18(4):507-17. doi: CliCa0804507517. Review. Japanese.

PMID:
18379033
10.

Denosumab and the current status of bone-modifying drugs in breast cancer.

Lee BL, Higgins MJ, Goss PE.

Acta Oncol. 2012 Feb;51(2):157-67. doi: 10.3109/0284186X.2011.633555. Epub 2011 Dec 12. Review.

PMID:
22150116
11.

Moving into the future: treatment of bone metastases and beyond.

Hortobagyi GN.

Cancer Treat Rev. 2005;31 Suppl 3:9-18. Epub 2005 Oct 24. Review.

PMID:
16249057
12.

Multidisciplinary approach to the treatment of bone metastases: Osteo-Oncology Center, a new organizational model.

Ibrahim T, Flamini E, Fabbri L, Serra P, Mercatali L, Ricci R, Sacanna E, Falasconi MC, Casadei R, Galassi R, Giannini M, Bazzocchi O, Calzolari F, Nunziatini R, Gaudio M, Maltoni M, Amadori D.

Tumori. 2009 May-Jun;95(3):291-7.

13.

Impact of denosumab on bone mass in cancer patients.

Brown-Glaberman U, Stopeck AT.

Clin Pharmacol. 2013 Jul 4;5:117-29. doi: 10.2147/CPAA.S30330. Print 2013.

14.

The NCI All Ireland Cancer Conference.

Johnston PG, Daly PA, Liu E.

Oncologist. 1999;4(4):275-277.

15.

A new emergency in oncology: Bone metastases in breast cancer patients (Review).

Ibrahim T, Mercatali L, Amadori D.

Oncol Lett. 2013 Aug;6(2):306-310. Epub 2013 Jun 4.

16.

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD003474.

PMID:
16034900
17.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
18.

Markers of bone turnover for the management of patients with bone metastases from prostate cancer.

Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD.

Br J Cancer. 2000 Feb;82(4):858-64.

19.

Clinical usefulness of bisphosphonates in oncology: treatment of bone metastases, antitumoral activity and effect on bone resorption markers.

Verì A, D'Andrea MR, Bonginelli P, Gasparini G.

Int J Biol Markers. 2007 Jan-Mar;22(1):24-33. Review.

PMID:
17393358
20.

Markers of bone turnover in bone metastases.

Fontana A, Delmas PD.

Cancer. 2000 Jun 15;88(12 Suppl):2952-60. Review.

PMID:
10898339
Items per page

Supplemental Content

Write to the Help Desk